Why Food OEM Projects Fail: Scope Creep, Cost Drift and Stopping Rules
In food contract manufacturing, the projects that genuinely fail are rarely the ones that cannot be made technically. Factories see plenty of partnerships stall halfway: a dozen formulation rounds, six months of samples, tooling cut and discarded, and a final cost far from the original discussion, until both sides lose energy and the project quietly dies. Reviewing these cases shows that collapse is seldom caused by one thing. It is several small problems stacking up, each tolerable alone, unbearable together. This article reviews four typical failure paths and sets out practical rules for pre-project review, change freezing and deciding when to stop - so that projects are rescued while they can still be rescued.
Path one: scope creep turns development into a bottomless pit
The most common starting point is requirement drift. The customer initially wants a base formula; several rounds later the taste must change, the dosage form must change, a new selling point must be added, the cost must come down. Every change looks reasonable in isolation, yet together they amount to starting over. Change itself is not the problem - unbounded change is. A healthy process sets a threshold: classify requests into structural changes that affect design and parameter changes that only affect settings. Structural changes require re-assessment of timing, cost and feasibility with written confirmation; parameter changes are handled freely within a limited number of rounds. Set stage gates for the formula as well - once sensory character is confirmed and stability testing begins, the formula is frozen in principle, and any genuine exception goes through a fresh approval. That line is what keeps development resources from being consumed without limit.
Path two: cost drifts out of control
Cost rarely fails through one bad quotation. It fails through accumulation: a higher ingredient grade, an upgraded pack, two extra tests, a switch from simple to premium packaging. Each is justifiable; together the margin is gone. Transparency in quotation is the defence. Break the price into ingredients, excipients, packaging, processing, testing, tooling and logistics, and state the assumptions behind each - which grade of raw material, which price band, which order quantity for packaging. Then any change in conditions maps to a specific line in the quotation, and both sides read the same arithmetic. The danger is a single bundled number, where no later adjustment can be attributed and every discussion becomes a dispute.
Path three: compliance raised too late
The third path is discovering at the final stage that a claim, an ingredient or a label does not meet regulatory requirements, forcing a reformulation or a change of direction. Compliance tends to surface late because, unlike taste, it cannot be sensed immediately, so it drifts to the end of the queue. The sound approach is to bring compliance review forward to project initiation: check ingredient permissibility, the boundaries of claim wording and differences between target markets when positioning and key ingredients are set; review again when the formula is confirmed; and audit finally before label artwork is produced. Three checkpoints cost very little and block most rework. For products intended for export, where standards differ meaningfully between markets, early confirmation saves far more.
Path four: broken communication and unclear ownership
Many projects are not killed but starved of momentum. Typical symptoms: each side has a contact person but neither can make decisions; technical questions loop through email with nobody ruling; sample feedback arrives late while the factory has already scheduled other orders; when something goes wrong both sides wait for the other to move first. Behind all of it is unclear ownership. A workable improvement defines three interfaces: the customer names a single technical decision-maker, the factory names a project owner, and both agree a fixed communication rhythm and response times. Key milestones need written confirmation - formula, sample, artwork and production release - each tied to a specific responsibility and a next action.
Stopping: knowing when to walk away
Not every project deserves rescuing, and recognising the signals to stop matters just as much. Three are worth heeding. First, the timeline is already more than double that of comparable products with no sign of convergence. Second, cost has exceeded the upper end of the target range with no viable alternative. Third, the technical brief contains a fundamental contradiction - extremely low cost alongside a high active load, for instance - and neither side will revise the target. When these appear, an honest conversation is more responsible than continued spending. Stopping does not mean falling out: options include scaling down to a simpler product, splitting the project into phases, or pausing while retaining the technical work already completed. Turning stopping into a normal, process-driven decision damages a long-term relationship far less than dragging things out until both sides are exhausted.
Turn the review into a routine
A short quarterly review of stalled and delayed projects is worth running, answering only three questions: where did it stick, was there a warning signal at the time, and what will we do differently. The output need not be a long report, but it should harden into rules - more than two structural changes triggers a re-review, label artwork is finalised during sampling, a raw material price move beyond a set band reopens the quotation. Accumulated over time, these rules lift the project success rate noticeably. Contract manufacturing is a service business, and project discipline often influences whether customers stay more than production equipment does.
Projects do not fail suddenly. They fail as the sum of ignored small signals. Control scope, cost, compliance and communication early, and stop decisively when stopping is right, and OEM partnerships last far longer.
Related Products
Milk Thistle, Kudzu & Turmeric Beverage with Sea Buckthorn Puree & Honey | Herbal Oral Liquid OEM | Liquid Fruit & Vegetable Salad Fiber Drink | Dietary Fiber Meal Replacement Vegetable Juice Beverage OEM
About Guangzhou Mesen Health Biotechnology Co., Ltd
Guangzhou Mesen Health Biotechnology Co., Ltd is located in the Huashan Science and Technology Park, Huadu District, Guangzhou. The company has focused on OEM and ODM services for the big health industry for nearly 20 years, operating dedicated research, production, sales and management centres, and maintaining long-term strategic partnerships with well-known Chinese medicine colleges and research institutions. Capabilities span pressed candy, gummies, capsules, solid beverages, herbal teas, plant beverages, protein powders, dietary supplements and enzyme jelly - from formulation development through contract manufacturing. For details on minimum order quantities, sampling lead times and quotations, see our manufacturing advantages and product range, or contact us for a tailored proposal.
Further Reading
